Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for severe hospitalized COVID-19
IRCT20220112053701N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: C-reactive protein, Lactate dehydrogenase and 3 more. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20220112053701N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220112053701N1.